PB 85 of 2020
National Health (Originator Brand) Amendment Determination 2020 (No. 5)
I, Thea Daniel, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination.
Dated 26 August 2020
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments 2
National Health (Originator Brand) Determination 2015 (PB 100 of 2015) 2
This instrument is the National Health (Originator Brand) Amendment Determination 2020 (No. 5).
This instrument may also be cited as PB 85 of 2020.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 September 2020 |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 99ADB(6B) of the National Health Act 1953
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Originator Brand) Determination 2015 (PB 100 of 2015)
1 Schedule 1, (table item 143)
Repeal the items:
143 | Metformin | Diabex Diabex 850 Diabex 1000 Diabex XR Diabex XR 1000 |
|
|
Substitute:
143 | Metformin | Diabex Diabex 850 Diabex 1000 Diabex XR 500 Diabex XR 1000 |
|
|
2 Schedule 1, (table item 156)
Repeal the items:
156 | Morphine | Hospira Pty Limited | Injection |
|
|
| MS Contin MS Contin Suspension 100 mg MS Contin Suspension 20 mg MS Contin Suspension 200 mg MS Contin Suspension 30 mg MS Contin Suspension 60 mg |
|
|
Substitute:
156 | Morphine | DBL Morphine Pentahydrate | Injection |
|
|
| MS Contin MS Contin Suspension 100 mg MS Contin Suspension 20 mg MS Contin Suspension 200 mg MS Contin Suspension 30 mg MS Contin Suspension 60 mg |
|
|
3 Schedule 1, (table item 207)
Repeal the items:
207 | Salbutamol | Ventolin Rotacaps Ventolin CFC‑free Ventolin Ventolin Nebules |
|
|
Substitute:
207 | Salbutamol | Ventolin Rotacaps Ventolin CFC‑free Ventolin CFC-Free with dose counter Ventolin Nebules |
|
|
4 Schedule 1, (table item 229A)
Repeal the items:
229A | Tobramycin | Hospira Pty Limited Pfizer Australia Pty Ltd | Injection |
|
Tobi | Inhalation |
| ||
TOBI podhaler | Inhalation by mouth |
| ||
Tobrex | Application to the eye |
|
Substitute:
229A | Tobramycin | DBL Tobramycin Pfizer Australia Pty Ltd | Injection |
|
Tobi | Inhalation |
| ||
TOBI podhaler | Inhalation by mouth |
| ||
Tobrex | Application to the eye |
|